|Systematic (IUPAC) name|
|Molar mass||273.370 g/mol|
Tropanserin (INN; MDL-72,422) is a drug which acts as a potent and selective 5-HT3 receptor antagonist. It was investigated in clinical trials for the treatment of migraine in the 1980s but was never marketed.
Tropanserin can be prepared by the reaction of tropine with 3,5-dimethylbenzoyl chloride.
- Frank D. King; Brian John Jones; Gareth J. Sanger (22 October 1993). 5-Hydroxytryptamine-3 Receptor Antagonists. CRC Press. p. 244. ISBN 978-0-8493-5463-2. Retrieved 6 May 2012.
- Denis M. Bailey (1 August 1987). Annual Reports in Medicinal Chemistry. Academic Press. p. 44. ISBN 978-0-12-040522-0. Retrieved 6 May 2012.
- J. R. Fozard and M. W. Gittos, U.S. Patent 4,563,465 (1986) via Chem. Abstr., 105:54,608j(1986)
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|